Human African Trypanosomiasis
📧 Sign up to get email alerts when something new happens for Human African Trypanosomiasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients [Phase 2, Phase 3]
Clinical trial update reporting pharmacokinetic, efficacy, safety and tolerability data from a single-dose study of Acoziborole in paediatri…
-
EMA approval · 2026-02-27New single-dose oral treatment for human African trypanosomiasis (sleeping sickness)
EMA approved acoziborole as a single-dose oral treatment for both stages of gambiense human African trypanosomiasis, simplifying management …
-
CLINICAL_TRIALS trial_result · 2025-09-17Clinical Trial Update: Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense [Phase 2, Phase 3]
Phase 2/3 clinical trial update shows efficacy and safety data for Acoziborole (SCYX-7158) in Gambiense human African trypanosomiasis, with …
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects [Phase 2, Phase 3]
Safety and tolerability results for Acoziborole in gambiense human African trypanosomiasis seropositive subjects from a Phase 2/3 trial have…
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense [Phase 2, Phase 3]
Phase 2/3 trial updates indicate completed testing of fexinidazole for Human African trypanosomiasis due to Trypanosoma brucei rhodesiense, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-09-20FDA Approved: FEXINIDAZOLE — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for fexinidazole submitted by Sanofi-Aventis U.S. LLC. This action updates the regulatory record for…
-
CLINICAL_TRIALS trial_result · 2024-06-07Clinical Trial Update: Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage [Phase 3]
Phase 3 trial results for fexinidazole in human African trypanosomiasis (Trypanosoma brucei gambiense) have been completed with results post…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT) [Phase 3]
Phase 3 clinical trial update for stopping transmission of gambiense human African trypanosomiasis; status is not yet recruiting.
-
FDA approval · 2021-12-15FDA Approved: FEXINIDAZOLE — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for fexinidazole from Sanofi-Aventis U.S. LLC, updating the product label (and indications) for the …
-
FDA approval · 2021-07-16FDA Approved: FEXINIDAZOLE — Original Application (Sanofi-Aventis U.S. LLC)
FDA approved fexinidazole (Sanofi-Aventis U.S. LLC) for the treatment of human African trypanosomiasis (sleeping sickness) in the United Sta…
-
CLINICAL_TRIALS trial_result · 2020-06-24Clinical Trial Update: Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study [Phase 2, Phase 3]
Clinical trial update on fexinidazole for early-stage Human African Trypanosomiasis (HAT) in T.b. gambiense, reporting efficacy and safety f…
-
CLINICAL_TRIALS trial_result · 2020-06-24Clinical Trial Update: Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study [Phase 2, Phase 3]
Prospective multicenter trial evaluating efficacy and safety of fexinidazole in children ≥6 years old and >20 kg with HAT due to T.b. gambie…
-
CLINICAL_TRIALS trial_result · 2018-02-20Clinical Trial Update: Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 [Phase 2, Phase 3]
Pivotal study update for fexinidazole in stage 2 human African trypanosomiasis (sleeping sickness) with completed status across Phase 2 and …
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole [Phase 1]
First-in-man Phase 1 clinical trial of fexinidazole for human African trypanosomiasis has been completed.
-
CLINICAL_TRIALS research · 2017-03-31Clinical Trial Update: Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food [Phase 1]
Phase 1 multiple-dose study of fexinidazole for human African trypanosomiasis evaluating safety, tolerability, and pharmacokinetics with a l…
-
CLINICAL_TRIALS trial_result · 2016-10-27Clinical Trial Update: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) [NA]
A completed study (NIDIAG-Fever) evaluated rapid diagnostic tests and clinical/laboratory predictors to diagnose tropical diseases in patien…
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis [Phase 3]
Phase 3 results compare the efficacy and safety of the eflornithine-nifurtimox combination versus eflornithine alone in human African trypan…
-
CLINICAL_TRIALS trial_result · 2015-09-18Clinical Trial Update: Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 [Phase 1]
A first-in-man, Phase 1 trial of SCYX-7158 for Human African Trypanosomiasis has completed, with DNDi listed as sponsor.
-
CLINICAL_TRIALS trial_result · 2013-05-31Clinical Trial Update: Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase [Phase 4]
A Phase 4 study evaluates tolerability, feasibility, and effectiveness of nifurtimox-eflornithine combination therapy (NECT) for late-stage …
-
CLINICAL_TRIALS trial_result · 2008-12-05Clinical Trial Update: A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis [Phase 2]
A Phase 2 trial of DB289 for Stage I African trypanosomiasis sponsored by Immtech Pharmaceuticals has completed.
-
CLINICAL_TRIALS trial_result · 2007-06-21Clinical Trial Update: Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda [Phase 2, Phase 3]
A late-stage trial of the eflornithine plus nifurtimox combination for human African trypanosomiasis in West Nile, Uganda has been terminate…